



## Exelixis Announces Webcasts of June Investor Conference Presentations

June 2, 2011

SOUTH SAN FRANCISCO, Calif., Jun 01, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) will present at the following investor conferences this month:

- **Jefferies Global Healthcare Conference:** Gisela Schwab, MD, the company's executive vice president and chief medical officer, will present at 12:30 p.m. EDT / 9:30 a.m. PDT on Thursday, June 9, in New York.
- **Goldman Sachs Healthcare Conference:** Michael Morrissey, PhD, the company's president and chief executive officer, will present at 1:40 p.m. EDT / 10:40 a.m. PDT on Thursday, June 9, in Palos Verdes, California.

During their respective presentations, Dr. Schwab and Dr. Morrissey will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer, ovarian cancer, and other tumor types, as presented at the 2011 ASCO Annual Meeting (June 3-7, Chicago). They will also discuss the pivotal trial plans and regulatory strategy for cabozantinib, and provide a general business update.

Both presentations will be webcast and may be accessed via the Event Calendar page under Investors at [www.exelixis.com](http://www.exelixis.com).

### About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Exelixis, Inc.  
Charles Butler, 650-837-7277  
Vice President, Investor Relations and Corporate Communications  
[cbutler@exelixis.com](mailto:cbutler@exelixis.com)